No Data
No Data
Express News | Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Arcturus Therapeutics (ARCT) Gets a Hold From Leerink Partners
Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $45
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $60
Why Investors Shouldn't Be Surprised By Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 31% Share Price Plunge